Cardiome Announces Launch of BRINAVESS in Canada

Cardiome Pharma received authorization from Health Canada to start selling BRINAVESS in Canada.

Cardiome Pharma (NASDAQ:CRME; TSX:COM) received authorization from Health Canada to start selling BRINAVESS in Canada.
As quoted in the press release:

BRINAVESS^® is indicated for the rapid conversion of recent onset atrial fibrillation (“AF”) to sinus rhythm for: non-surgery patients with AF < 7 days; and post-cardiac surgery patients with duration of AF < 3 days. BRINAVESS^® is not recommended for conversion of atrial flutter to sinus rhythm. The product is currently available on the Ontario formulary, with a broader launch anticipated in the third quarter of this year as more provinces are expected to include BRINAVESS^® in the provincial formularies.
“The launch of BRINAVESS^® in Canada marks the entry of this important treatment into one of the last remaining major markets in the world where BRINAVESS^® was previously not available for patients,” said Hugues Sachot, Cardiome’s Chief Commercial Officer. “Our commercial team has worked diligently with our hospital customers in anticipation of first commercial sale, and we are ready for sales to commence ahead of our previously guided fourth quarter timeline.”
“This is exciting progress for Cardiome as we continue to build a pharmaceutical company focused on bringing acute care medicines to physicians and patients in hospitals around the world,” said William Hunter, M.D., CEO and President of Cardiome. “This milestone is particularly gratifying as BRINAVESS^® was discovered by Canadian researchers and will now reach hospitals in Canada in order to help patients suffering from acute onset atrial fibrillation.”